Genprex Announces Sponsored Research Agreement With The University Of Michigan Rogel Cancer Center To Study TUSC2, The Tumor Suppressor Gene Used In Genprex's Lead Drug Candidate, Reqorsa Gene Therapy, In Combination With ALK-Inhibitors In ALK-EML4 Positive Translocated Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Genprex, Inc. has entered into a Sponsored Research Agreement with the University of Michigan Rogel Cancer Center to study the TUSC2 gene in combination with ALK-inhibitors for lung cancer treatment. This collaboration could expand the potential patient population for Genprex's Reqorsa Gene Therapy.
October 24, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genprex has partnered with the University of Michigan to study its lead drug candidate, Reqorsa Gene Therapy, in combination with ALK-inhibitors for lung cancer. This could potentially expand the therapy's patient base.
The partnership with a reputable institution like the University of Michigan could enhance the credibility and potential market reach of Genprex's Reqorsa Gene Therapy. The study's focus on a specific lung cancer type may lead to new treatment options, potentially increasing the drug's applicability and market size.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100